Casro Issues Statement On Adverse Event Reporting In Routine Surveys Conducted In The Pharmaceutical Arena

Share Article

Major Survey Research Trade Organization Cautions on Dangers in Using Routine Pharmaceutical Surveys as a Component of the “Pharmacovigilence” Process

The Board of Directors of CASRO voted last week on issuing a statement to caution the pharmaceutical industry on requiring routine pharmaceutical surveys to report Adverse Events in the course of the research. The Board outlined in the statement the reasons for taking this position.

The Board statement follows:

CASRO believes that market research organizations should not be required to assume responsibility for formal reporting of adverse events (AE) uncovered in the course of routine pharmaceutical market research because it is not a methodologically sound approach to post-market surveillance and it exposes research organizations to unacceptable legal and ethical risk.

However, in the event that a research organization chooses to accept the responsibility of reporting AE, we urge that, at a minimum, the organization obtain contractual terms that:

(1) fully specify all the conditions and procedures associated with those adverse reporting requirements, including stipulations associated with collection of both qualitative and quantitative data, as well as procedures to be taken in the event that respondents refuse permission;

(2) endorse a policy by which respondents are informed at the start of the research that any mention of product dissatisfaction will require that the organization submit an AE report on their behalf if one has not already been filed;

(3) fully waive, and indemnify the market research organization against, any and all legal liabilities arising as a result of its AE reporting responsibilities.

While CASRO believes these terms extend some measure of legal protection to member organizations and help to safeguard the ethical integrity of the research process, they do not overcome CASRO's overriding concerns about the impracticality and inadvisability of requiring routine market research studies to serve as a direct instrument of the “pharmacovigilence” process.

CASRO believes that we, as an industry, are better-equipped to advance pharmacovigilence in a different way. Recognizing that the industry’s extensive contact with patients and physicians puts us in a unique position to encourage and facilitate AE reporting by those who experience them and the medical professionals who observe them, CASRO recommends that research organizations play an indirect role, by reminding respondents of the importance of AE reporting and providing them with information to help them do so.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Harry Heller
Email >
Visit website